The emergence of mephedrone along with other synthetic cathinones has introduced worries for lawmakers and regulatory companies tasked with controlling the proliferation of latest psychoactive substances. The dynamic character of artificial drug manufacturing, coupled with the power of chemists to modify molecular buildings to evade legal restricti